Drugs / TQ-B3395
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02944864 | Sep 2017 → May 2021 | cancer of unknown primary site | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQ-B3395 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02944864 ↗ |
| Route | Oral | “TQ-B3395 p.o. qd” NCT02944864 ↗ |